JAK2 and myeloproliferative neoplasm: For WBC, statistically significant difference was found between MPNs with positive vs negative JAK2 V617F mutation (mean WBC difference = 4.84 × 109/L, p < 0.001), and among MPN sub-types (p < 0.001).